The estimated Net Worth of Andrew Cheng is at least $23.8 Million dollars as of 16 August 2024. Andrew Cheng owns over 24,538 units of Akero Therapeutics Inc stock worth over $15,555,311 and over the last 5 years he sold AKRO stock worth over $2,783,269. In addition, he makes $5,431,810 as President, Chief Executive Officer, and Director at Akero Therapeutics Inc.
Andrew has made over 39 trades of the Akero Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 24,538 units of AKRO stock worth $15,214 on 16 August 2024.
The largest trade he's ever made was exercising 75,000 units of Akero Therapeutics Inc stock on 4 March 2024 worth over $1,287,750. On average, Andrew trades about 17,016 units every 27 days since 2019. As of 16 August 2024 he still owns at least 607,155 units of Akero Therapeutics Inc stock.
You can see the complete history of Andrew Cheng stock trades at the bottom of the page.
Dr. Andrew Cheng M.D., Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Cheng has served as our President and Chief Executive Officer since September 2018. Before joining the Company, Dr. Cheng was formerly at Gilead Sciences, Inc., a biotechnology company, as the Chief Medical Officer from March 2018 through September 2018, Executive Vice President from February 2015 through September 2018 and Senior Vice President from February 2009 through February 2015. During his nearly 20 year tenure, he was responsible for the clinical development for the HIV program resulting in 11 FDA/EMA approved products. His past responsibilities also included medical affairs and the creation of the development operations department (regulatory affairs, clinical operations, pharmacovigilance, project management, clinical pharmacology and biometrics) which covered clinical development support in multiple therapeutic areas including oncology, inflammation, respiratory, cardiovascular, HIV and liver diseases. Dr. Cheng has served on the board of directors of Syntimmune, Inc., a biotechnology company, which was acquired by Alexion. Dr. Cheng holds a B.A. in biology from the Johns Hopkins University and a M.D. and Ph.D. in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA and was board certified in internal medicine.
As the President, Chief Executive Officer, and Director of Akero Therapeutics Inc, the total compensation of Andrew Cheng at Akero Therapeutics Inc is $5,431,810. There are no executives at Akero Therapeutics Inc getting paid more.
Andrew Cheng is 53, he's been the President, Chief Executive Officer, and Director of Akero Therapeutics Inc since 2018. There are 5 older and 8 younger executives at Akero Therapeutics Inc. The oldest executive at Akero Therapeutics Inc is Dr. Timothy Rolph, 67, who is the Co-Founder & Chief Scientific Officer.
Andrew's mailing address filed with the SEC is C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at Akero Therapeutics Inc have traded over $146,260,704 worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth $104,250,550 . The most active insiders traders include Group, Llc Green Jeremy Red..., Trust Blue Horizon Enterpri..., and G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,642,344. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth $133,600.
akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
Akero Therapeutics Inc executives and other stock owners filed with the SEC include: